Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals PLC    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Hikma Pharmaceuticals : Surging COVID-19 cases, U.S.-China tensions keep London stocks muted

share with twitter share with LinkedIn share with facebook
08/07/2020 | 04:14am EDT

* FTSE 100 down 0.1%, FTSE 250 off 0.3%

Aug 7 (Reuters) - Trading in London-listed shares was subdued on Friday as rising COVID-19 cases and U.S.-China tensions dented sentiment at the end of a week marked by largely upbeat quarterly earnings and improving economic data.

The blue-chip FTSE 100 was down 0.1% but still on course for its first weekly gain in three as investors bet on more stimulus to drive a post-pandemic economic rebound.

The mid-cap FTSE 250 dipped 0.3%, with losses in industrial, energy and tech-related stocks offsetting gains for consumer goods, healthcare and utility firms.

Stocks in Asia took a hit earlier in the day as Sino-U.S. tensions escalated with U.S. President Donald Trump banning transactions with two popular Chinese apps, Tencent's WeChat and ByteDance's Tiktok.

Hikma Pharmaceuticals Plc jumped 7.4% to the top of the FTSE 100 after raising its annual sales forecast for two of its biggest divisions and reporting higher first-half profit.

But TP ICAP Plc, the world's largest inter-dealer broker, fell 5.4% as it signalled a tepid start to the second half of the year. (Reporting by Sagarika Jaisinghani in Bengaluru; Editing by Subhranshu Sahu)


Stocks mentioned in the article
ChangeLast1st jan.
HIKMA PHARMACEUTICALS PLC -2.08% 2548 Delayed Quote.30.69%
TP ICAP -1.82% 189.2 Delayed Quote.-52.97%
share with twitter share with LinkedIn share with facebook
All news about HIKMA PHARMACEUTICALS PLC
10/20HIKMA PHARMACEUTICALS : and Arecor Expand Collaboration
AQ
09/23HIKMA PHARMACEUTICALS : provides update on status of ANDA for generic Advair Dis..
AQ
09/04HIKMA PHARMACEUTICALS : receives favourable court ruling for its generic Vascepa
AQ
09/03HIKMA PHARMACEUTICALS : receives favourable court ruling for its generic Vascepa..
PR
08/31HIKMA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and v..
CO
08/20HIKMA PHARMACEUTICALS PLC : Ex-dividend day for interim dividend
FA
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
More news
Financials (USD)
Sales 2020 2 326 M - -
Net income 2020 405 M - -
Net Debt 2020 327 M - -
P/E ratio 2020 20,0x
Yield 2020 1,42%
Capitalization 7 813 M 7 839 M -
EV / Sales 2020 3,50x
EV / Sales 2021 3,18x
Nbr of Employees 8 600
Free-Float 67,6%
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 33,12 $
Last Close Price 33,90 $
Spread / Highest target 15,3%
Spread / Average Target -2,31%
Spread / Lowest Target -45,9%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Henriette Nielsen Executive Vice President-Business Operations
Khalid Walid Hosni Nabilsi Chief Financial Officer
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS PLC30.69%7 839
JOHNSON & JOHNSON-1.86%376 848
ROCHE HOLDING AG-4.22%283 828
PFIZER INC.-4.47%207 994
MERCK & CO., INC.-14.25%197 256
NOVARTIS AG-19.31%180 257